Biogen (BIIB) | Stock Overview & Key Data
Biogen Performance Comparison
Stock Range
Today's Range
Low: $137.59
High: $140.20
on August 21, 2025
52 Week Range
Low: $110.04
High: $207.59
on April 9, 2025
on August 21, 2024
All-Time High: $480.18 on March 16, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$20.2B
EPS
10.45
P/E Ratio (TTM)
13.19
Forward P/E
8.27
P/B Ratio
1.15
PEG Ratio
8.27
Div. Yield
N/A
ROE
9.13%
Beta
0.133
Debt to Equity
37.40
Financial Highlights
Profitability
Gross Margin
77.13%
Operating Margin
34.61%
Profit Margin
15.31%
Returns and Earnings
Return on Assets (TTM)
5.62%
Return on Equity (TTM)
9.13%
EBITDA
$3.3B
Net Income (TTM)
$1.5B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$68.60
Quarterly Revenue Growth (YoY)
7.30%
Quarterly Earnings Growth (YoY)
8.80%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Biogen BIIB | 20.21B Large-cap | 3.10% | 13.40% | 9.70% | -1.08% | -7.25% | -32.14% | -29.95% | -50.57% |
| Eli Lilly and LLY | 618.46B Mega-cap | 3.71% | -6.87% | -2.09% | -18.76% | -8.77% | -25.50% | 124.94% | 381.76% |
| Johnson & Johnson JNJ | 428.20B Mega-cap | 2.41% | 8.86% | 16.81% | 10.25% | 24.24% | 9.02% | 8.92% | 16.46% |
| Amgen AMGN | 159.61B Large-cap | 1.88% | -0.04% | 9.00% | -2.39% | 14.07% | -10.05% | 22.90% | 16.85% |
| Gilead Sciences GILD | 146.39B Large-cap | -2.42% | 7.26% | 7.82% | 5.63% | 26.40% | 51.38% | 86.21% | 77.97% |
| Pfizer PFE | 143.96B Large-cap | 2.51% | 6.10% | 11.72% | -2.13% | -3.27% | -10.93% | -45.02% | -28.44% |
Ownership & Short Interest
Insider Ownership
0.15%
Institutional Ownership
92.78%
Shares Short
4M
Short Ratio
2.97
Short % of Shares Outstanding
3.49%
Average 10-Day Volume
1M
Average 90-Day Volume
1M
Biogen Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Biogen would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BIIB's 52-week high and low?
- In the last 52 weeks, Biogen reached a high of $207.59 (on August 21, 2024) and a low of $110.04 (on April 9, 2025).
- What is the market cap and P/E ratio for BIIB?
- Curious about Biogen's size and valuation? Its market capitalization stands at 20.21B. When it comes to valuation, the P/E ratio (trailing twelve months) is 13.19, and the forward P/E (looking ahead) is 8.27.
- Does BIIB pay dividends? If so, what's the yield?
- As for dividends, Biogen isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Biogen's main competitors or similar companies to consider before investing?
When looking at Biogen, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY618.46B Healthcare Drug Manufacturers - General -25.50% 124.94% Johnson & Johnson
JNJ428.20B Healthcare Drug Manufacturers - General 9.02% 8.92% Amgen
AMGN159.61B Healthcare Drug Manufacturers - General -10.05% 22.90% Gilead Sciences
GILD146.39B Healthcare Drug Manufacturers - General 51.38% 86.21% Pfizer
PFE143.96B Healthcare Drug Manufacturers - General -10.93% -45.02% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Biogen Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Biogen's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 9.13%, the Debt to Equity ratio from the most recent quarter is 37.40, and its Gross Profit Margin stands at 77.13%.
- What is the recent revenue and earnings growth for BIIB?
- Looking at Biogen's growth, its revenue over the trailing twelve months (TTM) was $10B. Compared to the same quarter last year (YoY), quarterly revenue grew by 7.30%, and quarterly earnings saw a YoY growth of 8.80%.
- How much of BIIB stock is held by insiders and institutions?
- Wondering who owns Biogen stock? Company insiders (like executives and directors) hold about 0.15% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 92.78%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.